<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[《中华放射医学与防护杂志》编辑部 -->放射生物学基础与应用]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[放射生物学与临床放射治疗互鉴发展]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190801&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/8/19 17:42:58</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[刘晓冬]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190801&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The challenges of precision radiotherapy technology to the traditional theory of radiobiology]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190802&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[With the development of modern computing technology and medical physics, radiotherapy has made great progress. The theoretical basis of radiobiology seems to lag behind the clinical application of radiotherapy, which hampers the further improvement of treatment efficacy and the optimization of treatment modality. In this paper, some emerging challenges of precision radiotherapy technology to the traditional theory of radiobiology, such as radiosensitivity, dose-response curve and survival curve, linear-quadratic model, 4Rs theory, as well as the interaction between cancer and microenvironment, radiation-induced second primary cancers (RISPC), will be discussed. The interplay between precision radiotherapy and traditional radiobiology theories will be addressed with the aim to potentially solve some of the challenging problems.]]></description>
<pubDate>2019/8/19 17:42:58</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[Ma Shumei,Liang Zhenzhen,Chen Qiao,Liu Rui,Guo Yutian,Liu Xiaodong]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190802&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The 4Rs in radiation therapy]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190803&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[It has been realized that the 4Rs (repair, repopulation, redistribution, and reoxygenation) would affect the result of cell irradiation, and thus radiation treatment. The 4Rs each occurs at different dose rates, usually very low dose rates. Depending on the dose rate used for treatment, the corresponding R should be included in the linear-quadratic equation (LQ) and biological effective dose (BED) calculation. For low dose rate brachytherapy(LDR) especially permanent implant, all the 4Rs should be included in LQ for BED calculation. The 4Rs, especially repair and repopulation, play a critical role in dose fractionation. Various dose fractionation schemes such as hyperfractionation and hypofractionation are determined in consideration of the 4Rs. Stereotactic radiation therapy uses hypofractionation with high fractional doses and combine with high accuracy target localization techniques to achieve high local control rates compared to conventional dose fractionation schemes. The 4Rs have been taken into account for LDR and permanent implant. Recently, LQ for permanent implant brachytherapy has been modified to include all the 4Rs for gynecological malignancy <sup>131</sup>Cs permanent implants. Including the 4Rs in radiation therapy has significantly improved the effectiveness and efficiency of radiation therapy for cancer treatment.]]></description>
<pubDate>2019/8/19 17:42:58</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[Luo Wei]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190803&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Low-dose radiation and Alzheimer's disease: Neuronal effects and a potential modality for therapy?]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190804&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Exposure to low-dose radiation (LDR, mostly less than 100 mGy) may reduce the vulnerability of exposed tissues to subsequent high-dose radiation (HDR)-induced damage, a phenomenon known as adaptive responses, which occurs via mechanisms including anti-inflammation and anti-oxidation. Alzheimer's disease (AD) is a type of dementia that causes problems with memory, thinking, and behavior. Using the available literature, this review will examine whether there is any effect of LDR on AD. The available evidence shows that although LDR can alter the expression of some genes related to AD such as Apbb1, Lrp1, and Il1α, these alterations do not cause AD-like syndromes in animals, suggesting that LDR may also simultaneously upregulate several protective mechanisms that prevent the eventual development of AD. Furthermore, LDR seems capable of improving the symptoms of AD, as evidenced by the experience of an 81-year-old female AD patient. This patient was diagnosed with AD more than 10 years ago and gradually progressed to advanced AD in 2015, despite routine treatment. The patient then received about 12 computed tomography scans (about 40 mGy each) up until Nov. 2017, which significantly improved her quality of life and reduced several AD symptoms. The improvement in this patient's medical condition led to a few recent clinical trials investigating the effects of LDR on AD. To date, there is no efficient therapy available for AD, thus whether exposure to LDR at 100 mGy can provide a preventive or therapeutic effect for AD is an important issue. If LDR is a potential treatment for AD, as suggested by this reported case, this non-invasive approach would also bear the merit that it would be unlikely to cause a significant radiation health risk, as the LDR could be delivered locally to the head without any impact on other organs.]]></description>
<pubDate>2019/8/19 17:42:58</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[Feng Li,Liu Qiang,Wang Bing,Cai Lu]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190804&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[近距离治疗的临床放射生物学]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190805&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[近距离治疗是将放射性同位素植入或置于肿瘤周边的一种技术。中心高剂量及随着距离的增加剂量迅速衰减是其最大的特点。近距离治疗主要包括低剂量率、高剂量率和脉冲剂量率3种。近距离治疗的最大优势是保证肿瘤组织充足剂量的基础上降低周围正常组织的放射性损伤。临床近距离治疗技术的进步与其放射生物学特点联系紧密。临床近距离治疗放射生物学的基本概念主要包括剂量率效应、放射性损伤的修复、再氧合、细胞周期的再分布及再群体化。探索近距离治疗放射生物学与临床近距离治疗效果的关系，利用近距离治疗的放射生物学特点，指导临床上近距离治疗的具体应用需要大量转化医学的工作。最终的目的是增加肿瘤局部控制率、降低不良反应及提高患者最终的生存期。]]></description>
<pubDate>2019/8/19 17:42:58</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[刘忠山,李云峰,任晓俊,林霞,王红勇,于多,张宝玉,王铁君,郭杰]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190805&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[放射治疗联合免疫检查点抑制剂的不良反应]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190806&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[放射治疗与免疫检查点抑制剂（immune-checkpoint inhibitors，ICI）在抗肿瘤方面具有协同作用，这种作用涉及与免疫系统间的复杂效应机制，并可能改善肿瘤患者的临床结果。然而，放疗联合ICI协同调节免疫应答的同时也可能引发治疗相关不良反应。鉴于联合治疗的临床研究与实践日益增加，需要关注放疗和ICI联合研究中不良反应事件的发生风险，进而评估联合治疗的安全性。]]></description>
<pubDate>2019/8/19 17:42:59</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[孙枫淏,邢力刚]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190806&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[鞘氨醇-1-磷酸受体-1促进肿瘤转移与放疗抵抗的研究进展]]></title>
<link><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190807&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[远处转移是癌症治疗的主要障碍之一。鞘氨醇-1-磷酸受体-1（sphingosine-1-phosphate receptor 1，S1PR1）在恶性肿瘤中过度表达，通过激活下游信号通路增强细胞侵袭和迁移活性、调控上皮间质转化（EMT）以及诱导淋巴管与血管生成，最终导致肿瘤转移的发生。S1PR1与获得性放射抗性的产生也有密切关联。本文就S1PR1及其在肿瘤转移和放疗抵抗中的作用进行综述。]]></description>
<pubDate>2019/8/19 17:42:59</pubDate>
<category><![CDATA[放射生物学基础与应用]]></category>
<author><![CDATA[高梦丹,叶旭雪,卢立淮,王琼琼,周清宇,高雅,李益飞,谢聪颖]]></author>
<guid><![CDATA[http://www.cjrmp.net/zhfsyx/ch/reader/view_abstract.aspx?file_no=20190807&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>